Advancements in Drug Development and Formulation

whitePaper | November 21, 2022

Contract manufacturing can enhance the drug development process by creating effective processes, increasing manufacturing efficiencies, and reducing overhead costs.

whitePaper | October 3, 2022

Next-Generation Synthetic Biology Workflow Platform Codex DNA’s BioXp 9600 system is a next-generation high throughput platform intended for automated synthesis of gene fragments and clones from digital sequences.

whitePaper | February 20, 2023

Once the industry has normalized after a turbulent 2020, life sciences leaders can still count on continued change. The future will be challenging at best without the support of next-gen BI as life sciences navigate their businesses through new or growing competition, economic recovery, regulatory and political pressures, barriers to market access, and an increased demand for personalized medicine.

whitePaper | October 13, 2022

In our previous edition of the Clinical Trials Roundup1, we explored the acute disruptions that the COVID-19 pandemic brought to the clinical trials landscape in 2020.

whitePaper | July 13, 2023

Most medicines in development today target diseases affecting large sections of the global population. But now we are slowly beginning to see a rise in the interest of developing ”orphan drugs,” or pharmaceutical agents intended to treat rare diseases.

whitePaper | March 14, 2022

Over the past several years, biologics have gained significant traction in the pharmaceutical industry, representing more than $150 billion in global sales in 2013. By 2020 they are predicted to generate $290 billion in revenue and comprise 27 percent of the pharmaceutical market.i